p53 and atherosclerosis.
Tabas
I
I
D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency; D017209:Apoptosis; D001161:Arteriosclerosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D001854:Bone Marrow Cells / Q000378:metabolism; D001973:Bromodeoxyuridine; D002455:Cell Division; D004195:Disease Models, Animal; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000378:metabolism; D005487:Foam Cells / Q000378:metabolism / Q000473:pathology; D020287:In Situ Nick-End Labeling; D008077:Lipoproteins, LDL / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D008817:Mice, Mutant Strains; D009131:Muscle, Smooth, Vascular / Q000378:metabolism; D009336:Necrosis; D009569:Nitric Oxide / Q000494:pharmacology; D009687:Nuclear Proteins; D010587:Phagocytosis; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*
D001057:Apolipoproteins E; D008077:Lipoproteins, LDL; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; D009569:Nitric Oxide; C497207:Mdm2 protein, mouse; D051736:Proto-Oncogene Proteins c-mdm2; D001973:Bromodeoxyuridine